Results 221 to 230 of about 18,729 (264)

Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.

Chest, 2012
V. Tapson, F. Torres, F. Kermeen, A. Keogh, R. Allen, R. Frantz, D. Badesch, A. Frost, S. Shapiro, K. Laliberte, J. Sigman, C. Arneson, N. Galiè   +12 more
semanticscholar   +1 more source

Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans

Xenobiotica; the fate of foreign compounds in biological systems, 2012
S. Bruderer, G. Hopfgartner, M. Seiberling, J. Wank, P. Sidharta, A. Treiber, J. Dingemanse   +6 more
semanticscholar   +1 more source

An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin®), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension.

Regulatory toxicology and pharmacology : RTP, 2012
K. Owen, D. Cross, Mazin Derzi, Elizabeth T M Horsley, F. Stavros   +4 more
semanticscholar   +1 more source

Sildenafil improves diabetic vascular activity through suppressing endothelin receptor A, iNOS and NADPH oxidase which is comparable with the endothelin receptor antagonist CPU0213 in STZ‐injected rats

The Journal of pharmacy and pharmacology, 2011
Lu Luo, D. Dai, Yu-si Cheng, Qi Zhang, W. Yuan, Yin Dai   +5 more
semanticscholar   +1 more source

Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study.

American Journal of Respiratory and Critical Care Medicine, 2005
M. Wilkins, G. Paul, J. Strange, N. Tunariu, W. Gin-Sing, W. Banya, M. Westwood, A. Stefanidis, L. Ng, D. Pennell, R. Mohiaddin, P. Nihoyannopoulos, J. Gibbs   +12 more
semanticscholar   +1 more source

Incomplete inhibition of endothelin-1 pressor effects by an endothelin ETA receptor antagonist

European Journal of Pharmacology, 1993
J E Bird
exaly  

Improvement of bleomycin-induced pulmonary hypertension and pulmonary fibrosis by the endothelin receptor antagonist Bosentan.

Respiratory Physiology & Neurobiology, 2010
S. Schroll, M. Arzt, D. Sebah, Martin Nüchterlein, F. Blumberg, M. Pfeifer   +5 more
semanticscholar   +1 more source

[Endothelin receptor antagonist].

Nihon rinsho. Japanese journal of clinical medicine, 2000
S, Sakai, T, Miyauchi, Y, Sugishita
openaire   +3 more sources

Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension

Expert Opinion on Pharmacotherapy, 2007
Robyn J Barst
exaly  

Sitaxsentan: a novel endothelin-A receptor antagonist for pulmonary arterial hypertension

Expert Review of Cardiovascular Therapy, 2005
Allison C Widlitz, Robyn J Barst, Evelyn M Horn   +2 more
exaly